MCID: LRY005
MIFTS: 19

Laryngeal Small Cell Carcinoma malady

Categories: Cancer diseases, Respiratory diseases, Oral diseases

Aliases & Classifications for Laryngeal Small Cell Carcinoma

Aliases & Descriptions for Laryngeal Small Cell Carcinoma:

Name: Laryngeal Small Cell Carcinoma 12 14 69
Small Cell Carcinoma of Larynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7144
NCIt 47 C6025
UMLS 69 C1334378

Summaries for Laryngeal Small Cell Carcinoma

MalaCards based summary : Laryngeal Small Cell Carcinoma, also known as small cell carcinoma of larynx, is related to small cell carcinoma and laryngitis. An important gene associated with Laryngeal Small Cell Carcinoma is CNN1 (Calponin 1). The drugs Nicotine and Liver Extracts have been mentioned in the context of this disorder.

Related Diseases for Laryngeal Small Cell Carcinoma

Diseases related to Laryngeal Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 small cell carcinoma 9.9
2 laryngitis 9.9
3 sternum lymphoma 9.8 CNN1 TAGLN
4 lung occult large cell carcinoma 9.8 CNN1 TAGLN
5 uterine corpus myxoid leiomyosarcoma 9.7 CNN1 TAGLN

Graphical network of the top 20 diseases related to Laryngeal Small Cell Carcinoma:



Diseases related to Laryngeal Small Cell Carcinoma

Symptoms & Phenotypes for Laryngeal Small Cell Carcinoma

Drugs & Therapeutics for Laryngeal Small Cell Carcinoma

Drugs for Laryngeal Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3 Cholinergic Agents Phase 4,Phase 3
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
5 Nicotinic Agonists Phase 4
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Autonomic Agents Phase 4,Phase 3
8 Central Nervous System Stimulants Phase 4
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
12
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
13
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
16
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
17
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
18
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
19
Doxepin Approved Phase 3 1668-19-5 667477 667468
20
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
21 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
22 pancreatic polypeptide Phase 3
23 Analgesics Phase 3,Phase 2
24 Mitogens Phase 3,Phase 2,Phase 1
25 Adjuvants, Anesthesia Phase 3
26 Narcotics Phase 3
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
28 Analgesics, Opioid Phase 3
29 Anesthetics Phase 3
30 Vaccines Phase 3,Phase 2
31 Anesthetics, General Phase 3
32 Anesthetics, Intravenous Phase 3
33 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
34 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 1
36 Immunoglobulins Phase 3,Phase 2,Phase 1
37 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
38 Antidepressive Agents Phase 3,Phase 2
39 Psychotropic Drugs Phase 3,Phase 2
40 Antimetabolites Phase 3,Phase 1,Phase 2
41 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
42 Antibodies Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Central Nervous System Depressants Phase 3
46 Neuromuscular Agents Phase 3,Phase 1
47 Neuromuscular Blocking Agents Phase 3,Phase 1
48 Neuromuscular Depolarizing Agents Phase 3,Phase 1
49 Immunoglobulin G Phase 3,Phase 2
50
Histamine Phosphate Phase 3 51-74-1 65513

Interventional clinical trials:

(show top 50) (show all 106)
id Name Status NCT ID Phase
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
5 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3
6 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3
7 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
8 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
9 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Active, not recruiting NCT00820248 Phase 3
10 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3
11 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
12 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Active, not recruiting NCT00265941 Phase 3
13 Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx Terminated NCT00004227 Phase 3
14 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
15 Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Unknown status NCT01247246 Phase 2
16 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2
17 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
18 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2
19 Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx Completed NCT00498953 Phase 1, Phase 2
20 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
21 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
22 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
23 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2
24 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
25 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
26 Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia Completed NCT00056004 Phase 2
27 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2
28 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2
29 Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer Completed NCT00248560 Phase 2
30 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck Completed NCT00084318 Phase 2
31 Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00425750 Phase 2
32 BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00057850 Phase 1, Phase 2
33 S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer Completed NCT00100789 Phase 2
34 S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00006248 Phase 2
35 S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003908 Phase 2
36 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
37 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00055913 Phase 1, Phase 2
38 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2
39 S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00337129 Phase 2
40 PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery Completed NCT00276523 Phase 2
41 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2
42 A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) Completed NCT00589667 Phase 2
43 S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054054 Phase 2
44 Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00281840 Phase 2
45 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
46 Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot Recruiting NCT03010553 Phase 2
47 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers Recruiting NCT00900419 Phase 2
48 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting NCT03082534 Phase 2
49 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Active, not recruiting NCT02048020 Phase 2
50 Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT00096174 Phase 2

Search NIH Clinical Center for Laryngeal Small Cell Carcinoma

Genetic Tests for Laryngeal Small Cell Carcinoma

Anatomical Context for Laryngeal Small Cell Carcinoma

Publications for Laryngeal Small Cell Carcinoma

Articles related to Laryngeal Small Cell Carcinoma:

id Title Authors Year
1
Optimal postoperative treatment for composite laryngeal small cell carcinoma. ( 24159397 )
2013
2
KIT and platelet-derived growth factor receptor I+ gene expression in laryngeal small cell carcinoma. ( 20537211 )
2010
3
Long-term survival in response to combined chemotherapy and radiotherapy in laryngeal small cell carcinoma. ( 3028349 )
1986

Variations for Laryngeal Small Cell Carcinoma

Expression for Laryngeal Small Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Small Cell Carcinoma.

Pathways for Laryngeal Small Cell Carcinoma

GO Terms for Laryngeal Small Cell Carcinoma

Sources for Laryngeal Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....